Lymphocyte and Cytokine Disturbances in Polymyalgia Rheumatica

Caractérisation Des Anomalies Immunologiques au Cours de la Pseudopolyarthrite rhizomélique et Effets du Traitement Par Tocilizumab

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02888496

Acronym

TENOR-IMMUNO

Enrollment

Registered

2016-09-05

Start date

2015-01-31

Completion date

2015-06-30

Last updated

2016-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polymyalgia Rheumatica

Brief summary

Pathophysiology of polymyalgia rheumatica (PMR) is ill defined. This study aims at characterizing immunological abnormalities in PMR patients, and to assess the effects of tocilizumab therapy on this abnormalities.

Detailed description

Comparison of PMR patients and matched control subjects.

Interventions

DRUGtocilizumab

3 monthly IV infusions in PMR patients

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Yes

Inclusion criteria

* PMR patient included in the TENOR study with samples available

Exclusion criteria

* Patient not included in the TENOR study

Design outcomes

Primary

Measure	Time frame	Description
Proportion of blood lymphocyte populations (T cells, B cells, NK cells)	6 months	Lymphocyte subset analysis by flow cytometry

Secondary

Measure	Time frame	Description
Serum cytokine concentration measurement	6 months	Cytokine level measurements using an array and ELISAs

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026